Spark Therapeutics (NASDAQ:ONCE) Upgraded to Hold at Zacks Investment Research

Spark Therapeutics (NASDAQ:ONCE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. “

ONCE has been the topic of a number of other reports. ValuEngine downgraded shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Mizuho reissued a “hold” rating and set a $114.50 price objective on shares of Spark Therapeutics in a research report on Monday, August 12th. Thirteen research analysts have rated the stock with a hold rating, Spark Therapeutics currently has an average rating of “Hold” and an average target price of $106.00.

Shares of Spark Therapeutics stock opened at $111.30 on Tuesday. The company has a current ratio of 4.67, a quick ratio of 4.35 and a debt-to-equity ratio of 0.35. The company’s fifty day simple moving average is $108.19 and its two-hundred day simple moving average is $103.26. The company has a market cap of $4.28 billion, a P/E ratio of -52.75 and a beta of 2.05. Spark Therapeutics has a 12-month low of $34.53 and a 12-month high of $114.20.

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its position in shares of Spark Therapeutics by 4,568.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 887 shares of the biotechnology company’s stock worth $86,000 after buying an additional 868 shares during the period. CSat Investment Advisory L.P. purchased a new stake in shares of Spark Therapeutics in the 2nd quarter worth about $113,000. Nisa Investment Advisors LLC grew its position in shares of Spark Therapeutics by 651.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,165 shares of the biotechnology company’s stock worth $113,000 after buying an additional 1,010 shares during the period. Janney Montgomery Scott LLC purchased a new stake in shares of Spark Therapeutics in the 2nd quarter worth about $202,000. Finally, Ancora Advisors LLC purchased a new stake in shares of Spark Therapeutics in the 2nd quarter worth about $205,000. 88.36% of the stock is currently owned by hedge funds and other institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Featured Story: Bollinger Bands

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.